NO20026123L - Farmasöytiske sammensetninger - Google Patents

Farmasöytiske sammensetninger

Info

Publication number: NO20026123L
Authority: NO; Norway
Prior art keywords: pharmaceutical compositions; pharmaceutical; compositions
Prior art date: 2000-06-22

Application number

NO20026123A

Other languages

English (en)

Norwegian (no)

Other versions

NO20026123D0 (no

Inventor

Sabina Maria Ganter

Robert Frank Wagner

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-22

Filing date

2002-12-19

Publication date

2003-02-18

2002-12-19 Application filed by Novartis Ag filed Critical Novartis Ag

2002-12-19 Publication of NO20026123D0 publication Critical patent/NO20026123D0/no

2003-02-18 Publication of NO20026123L publication Critical patent/NO20026123L/no

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Obesity (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20026123A 2000-06-22 2002-12-19 Farmasöytiske sammensetninger NO20026123L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US59968700A	2000-06-22	2000-06-22
PCT/EP2001/006983 WO2001097805A2 (en)	2000-06-22	2001-06-20	Solid valsartan pharmaceutical compositions

Publications (2)

Publication Number	Publication Date
NO20026123D0 NO20026123D0 (no)	2002-12-19
NO20026123L true NO20026123L (no)	2003-02-18

Family

ID=24400655

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20026123A NO20026123L (no)	2000-06-22	2002-12-19	Farmasöytiske sammensetninger

Country Status (21)

Country	Link
EP (2)	EP1296677A2 (ja)
JP (3)	JP2003535895A (ja)
KR (2)	KR100659644B1 (ja)
CN (2)	CN1221256C (ja)
AU (2)	AU2001285768B2 (ja)
BR (1)	BR0111868A (ja)
CA (1)	CA2411882C (ja)
CZ (1)	CZ20024180A3 (ja)
EC (1)	ECSP024389A (ja)
HK (2)	HK1052868A1 (ja)
HU (1)	HUP0301390A3 (ja)
IL (2)	IL153428A0 (ja)
MX (1)	MXPA02012683A (ja)
NO (1)	NO20026123L (ja)
NZ (2)	NZ540748A (ja)
PL (1)	PL358290A1 (ja)
RU (1)	RU2333757C2 (ja)
SG (1)	SG162605A1 (ja)
SK (1)	SK18062002A3 (ja)
WO (1)	WO2001097805A2 (ja)
ZA (1)	ZA200210359B (ja)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE524176T1 (de) *	1998-12-23	2011-09-15	Novartis Pharma Gmbh	Valsartan tablette
EP1467728B1 (en) *	2002-01-17	2007-08-22	Novartis AG	Pharmaceutical compositions comprising valsartan and nep inhibitors
US7468390B2 (en)	2002-01-17	2008-12-23	Novartis Ag	Methods of treatment and pharmaceutical composition
GB0209265D0 (en)	2002-04-23	2002-06-05	Novartis Ag	Organic compounds
TWI299663B (en) *	2002-05-14	2008-08-11	Novartis Ag	Methods of treatment
WO2005013964A1 (ja)	2003-08-08	2005-02-17	Ajinomoto Co., Inc.	ナテグリニド含有製剤
WO2006021443A2 (en) *	2004-08-26	2006-03-02	Novartis Ag	Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator
PL2033629T3 (pl)	2004-12-24	2013-04-30	Krka	Stała kompozycja farmaceutyczna zawierająca walsartan
JP2009001520A (ja) *	2007-06-21	2009-01-08	Kowa Co	ジフェンヒドラミン含有固形製剤
EP2197416A1 (en)	2007-10-09	2010-06-23	Novartis Ag	Pharmaceutical formulation of valsartan
WO2009059605A1 (en) *	2007-11-08	2009-05-14	University Of Copenhagen	Small scale solid state screening
EP2067470A1 (en) *	2007-12-03	2009-06-10	Laboratorios Lesvi, S.L.	Pharmaceutical compositions containing valsartan and process for its preparation
SI2536396T1 (sl)	2010-02-16	2017-01-31	KRKA, tovarna zdravil, d.d.,Novo mesto	Postopek za pripravo oralnih trdnih odmernih oblik, ki obsegajo valsartan
CN102362865B (zh) *	2011-10-28	2013-06-26	山东司邦得制药有限公司	一种含有盐酸贝尼地平和缬沙坦的复方制剂及其应用
WO2013098576A1 (en)	2011-12-31	2013-07-04	Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi	Immediate release pharmaceutical composition of valsartan
WO2013098578A1 (en)	2011-12-31	2013-07-04	Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi	Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
CN103599084B (zh) *	2013-11-22	2018-10-30	威海迪素制药有限公司	一种降压组合物
CN112826806A (zh) *	2021-01-20	2021-05-25	海南皇隆制药股份有限公司	一种缬沙坦片制备方法和缬沙坦片
CN112807286A (zh) *	2021-01-20	2021-05-18	海南皇隆制药股份有限公司	一种缬沙坦分散片制备方法和缬沙坦分散片
EP4295839A1 (en)	2022-06-20	2023-12-27	KRKA, d.d., Novo mesto	Combination of valsartan and indapamide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PH30484A (en)	1990-02-19	1997-05-28	Ciba Geigy	Acy compounds pharmaceutical composition containing said compound and method of use thereof
CZ268896A3 (en) *	1994-03-17	1997-03-12	Ciba Geigy Ag	Pharmaceutical preparation for treating diabetic nephropathy and application of angiotensin ii antagonist for preparing thereof
US6071931A (en) *	1995-10-06	2000-06-06	Novartis Ag	AT1 -receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys
PT883401E (pt) *	1996-02-29	2003-03-31	Novartis Ag	Antagonista do receptor at1 para estimulacao da apoptose
EP0904060B1 (en) *	1996-05-20	2003-12-10	Janssen Pharmaceutica N.V.	Antifungal compositions with improved bioavailability
GB9613470D0 (en) *	1996-06-27	1996-08-28	Ciba Geigy Ag	Small solid oral dosage form
US6541669B1 (en) *	1998-06-08	2003-04-01	Theravance, Inc.	β2-adrenergic receptor agonists
SE9802973D0 (sv) *	1998-09-03	1998-09-03	Astra Ab	Immediate release tablet
ATE524176T1 (de) *	1998-12-23	2011-09-15	Novartis Pharma Gmbh	Valsartan tablette
MXPA02010090A (es) *	2000-04-12	2003-02-12	Novartis Ag	Combinacion de al menos dos compuestos seleccionados de los grupos de un antagonista del receptor at-1 o un inhibidor ace o un inhibidor de la hmg-co-a reductasa.

2001
- 2001-06-20 JP JP2002503289A patent/JP2003535895A/ja not_active Withdrawn
- 2001-06-20 CZ CZ20024180A patent/CZ20024180A3/cs unknown
- 2001-06-20 EP EP01965014A patent/EP1296677A2/en not_active Ceased
- 2001-06-20 EP EP09004205A patent/EP2072049A3/en not_active Withdrawn
- 2001-06-20 SK SK1806-2002A patent/SK18062002A3/sk unknown
- 2001-06-20 CN CNB018115527A patent/CN1221256C/zh not_active Expired - Fee Related
- 2001-06-20 CA CA2411882A patent/CA2411882C/en not_active Expired - Fee Related
- 2001-06-20 KR KR1020057013346A patent/KR100659644B1/ko not_active IP Right Cessation
- 2001-06-20 IL IL15342801A patent/IL153428A0/xx unknown
- 2001-06-20 AU AU2001285768A patent/AU2001285768B2/en not_active Ceased
- 2001-06-20 NZ NZ540748A patent/NZ540748A/en not_active IP Right Cessation
- 2001-06-20 SG SG200501782-7A patent/SG162605A1/en unknown
- 2001-06-20 MX MXPA02012683A patent/MXPA02012683A/es active IP Right Grant
- 2001-06-20 HU HU0301390A patent/HUP0301390A3/hu not_active Application Discontinuation
- 2001-06-20 AU AU8576801A patent/AU8576801A/xx active Pending
- 2001-06-20 CN CNB2005100510503A patent/CN100450478C/zh not_active Expired - Fee Related
- 2001-06-20 RU RU2003100507/15A patent/RU2333757C2/ru not_active IP Right Cessation
- 2001-06-20 NZ NZ522953A patent/NZ522953A/en not_active IP Right Cessation
- 2001-06-20 WO PCT/EP2001/006983 patent/WO2001097805A2/en active Search and Examination
- 2001-06-20 BR BR0111868-4A patent/BR0111868A/pt not_active Application Discontinuation
- 2001-06-20 PL PL01358290A patent/PL358290A1/xx not_active Application Discontinuation
- 2001-06-20 KR KR10-2002-7017469A patent/KR100525341B1/ko not_active IP Right Cessation
2002
- 2002-12-12 EC EC2002004389A patent/ECSP024389A/es unknown
- 2002-12-12 IL IL153428A patent/IL153428A/en not_active IP Right Cessation
- 2002-12-19 NO NO20026123A patent/NO20026123L/no unknown
- 2002-12-20 ZA ZA200210359A patent/ZA200210359B/xx unknown
2003
- 2003-07-08 HK HK03104842.9A patent/HK1052868A1/zh unknown
2006
- 2006-03-20 HK HK06103477.0A patent/HK1083452A1/xx unknown
2007
- 2007-01-11 JP JP2007003546A patent/JP2007091758A/ja not_active Withdrawn
2012
- 2012-08-02 JP JP2012172246A patent/JP2012211200A/ja active Pending

Also Published As

Publication number	Publication date
NZ540748A (en)	2007-04-27
EP1296677A2 (en)	2003-04-02
CN1679551A (zh)	2005-10-12
KR20050085978A (ko)	2005-08-29
IL153428A (en)	2013-12-31
JP2003535895A (ja)	2003-12-02
JP2012211200A (ja)	2012-11-01
PL358290A1 (en)	2004-08-09
HK1083452A1 (en)	2006-07-07
KR100659644B1 (ko)	2006-12-21
NO20026123D0 (no)	2002-12-19
KR100525341B1 (ko)	2005-11-02
CN1221256C (zh)	2005-10-05
WO2001097805A3 (en)	2002-08-29
BR0111868A (pt)	2003-07-01
EP2072049A2 (en)	2009-06-24
IL153428A0 (en)	2003-07-06
CN1437469A (zh)	2003-08-20
EP2072049A3 (en)	2009-12-30
SK18062002A3 (sk)	2003-07-01
AU2001285768B2 (en)	2005-03-10
HUP0301390A3 (en)	2005-04-28
HUP0301390A2 (hu)	2003-11-28
NZ522953A (en)	2005-10-28
CA2411882C (en)	2011-09-06
MXPA02012683A (es)	2003-04-25
CA2411882A1 (en)	2001-12-27
ECSP024389A (es)	2003-02-06
JP2007091758A (ja)	2007-04-12
CZ20024180A3 (cs)	2003-04-16
HK1052868A1 (zh)	2003-10-03
CN100450478C (zh)	2009-01-14
ZA200210359B (en)	2003-11-13
SG162605A1 (en)	2010-07-29
WO2001097805A2 (en)	2001-12-27
RU2333757C2 (ru)	2008-09-20
AU8576801A (en)	2002-01-02
KR20030019450A (ko)	2003-03-06

Publication	Publication Date	Title
AR028204A1 (es)	2003-04-30	Composiciones farmaceuticas electrohiladas
FI20105657A (fi)	2010-06-10	Farmaseuttisia koostumuksia
ITMI20010748A0 (it)	2001-04-06	Composizioni farmaceutiche
DK1524266T3 (da)	2007-06-25	Farmaceutisk sammensætning
NO20025450L (no)	2002-11-14	Ny farmasöytisk sammensetning
ATE303787T1 (de)	2005-09-15	Schergelzusammensetzungen
ITTO20010008A0 (it)	2001-01-10	Formulazione farmaceutica
FI20011478A0 (fi)	2001-07-05	Farmaseuttinen koostumus
PT1242087E (pt)	2004-06-30	Composicoes farmaceuticas
NO20033556L (no)	2003-10-09	Farmasöytiske formuleringer
NO20015175D0 (no)	2001-10-23	Farmasöytisk sammensetning
AR028197A1 (es)	2003-04-30	Composiciones antitranspirantes
AT7729U3 (de)	2006-01-15	Pharmazeutische zusammensetzungen enthaltend amlodipinmaleat
EE05020B1 (et)	2008-06-16	Glburiidi ravimkoostis
EE200300589A (et)	2004-02-16	Ravimkoostised
NO20026123L (no)	2003-02-18	Farmasöytiske sammensetninger
ATE369830T1 (de)	2007-09-15	Schweisshemmende zusammensetzungen
ATE314049T1 (de)	2006-01-15	Schweisshemmende zusammensetzungen
PT1239832E (pt)	2004-10-29	Composicoes farmaceuticas
FI20022128A (fi)	2003-06-06	Farmaseuttinen koostumus
NO20031095D0 (no)	2003-03-10	Farmasöytiske sammensetninger
DE60116858D1 (de)	2006-04-13	Zusammensetzung
FI4488U1 (fi)	2000-07-20	Farmaseuttinen koostumus
EE200200689A (et)	2004-06-15	Ravimkoostised
MXPA03001857A (es)	2003-06-04	Composicones medicinales.